Daily Stock Analysis, AGTC, Applied Genetic Technologies Corp, priceseries

Applied Genetic Technologies Corp. Daily Stock Analysis
Stock Information
Open
4.60
Close
4.48
High
4.60
Low
4.40
Previous Close
4.55
Daily Price Gain
-0.07
YTD High
4.81
YTD High Date
Apr 17, 2019
YTD Low
2.39
YTD Low Date
Jan 2, 2019
YTD Price Change
1.83
YTD Gain
69.06%
52 Week High
7.50
52 Week High Date
Oct 1, 2018
52 Week Low
2.26
52 Week Low Date
Dec 21, 2018
52 Week Price Change
-0.62
52 Week Gain
-12.16%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 2. 2018
3.75
Jan 16. 2018
4.04
9 Trading Days
7.65%
Link
LONG
Jan 22. 2018
4.15
Feb 1. 2018
4.57
8 Trading Days
10.18%
Link
LONG
Feb 28. 2018
3.85
Mar 12. 2018
4.34
8 Trading Days
12.84%
Link
LONG
Apr 11. 2018
4.00
Apr 25. 2018
4.67
10 Trading Days
16.85%
Link
LONG
May 14. 2018
5.05
May 22. 2018
5.36
6 Trading Days
6.17%
Link
LONG
Sep 18. 2018
4.25
Oct 8. 2018
6.24
14 Trading Days
46.82%
Link
Company Information
Stock Symbol
AGTC
Exchange
NasdaqGM
Company URL
http://www.agtc.com
Company Phone
386-462-2204
CEO
Susan B. Washer
Headquarters
Florida
Business Address
14193 NW 119TH TERRACE, SUITE #10, ALACHUA, FL 32615
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001273636
About

Applied Genetic Technologies Corp. is a clinical-stage biotechnology company, which engages in the development of gene therapy products designed to transform the lives of patients with severe diseases in ophthalmology. Its product candidates are designed to treat X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL.

Description

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops genetic therapies to treat patients with inherited diseases. Its lead products consist of four ophthalmology development programs across three targets, including X linked retinoschisis (XLRS) that is in a Phase I/II clinical trials for the treatment of an inherited retinal disease; X-linked retinitis pigmentosa (XLRP), which is enrolling patients in a Phase I/II clinical trials; and achromatopsia (ACHM) that is enrolling patients in a Phase I/II clinical trials. Applied Genetic Technologies Corporation has collaboration agreements with Biogen MA, Inc.; 4D Molecular Therapeutics; and Synpromics Limited. The company was founded in 1999 and is headquartered in Alachua, Florida.